Chemical compound extends survival by months, in mice
Pancreatic cancer is especially challenging to treat – only eight percent of patients are still alive five years after diagnosis. Chemotherapy and radiation therapy are of limited benefit, and even immunotherapy – which revolutionized treatment for other kinds of cancer by activating the body’s immune system to attack cancer cells – has been largely ineffective because pancreatic tumors have ways to dampen the immune assault.
Now, researchers at Washington University School of Medicine in St. Louis and Rush University in Chicago have found a chemical compound that promotes a vigorous immune assault against the deadly cancer. Alone, the compound reduces pancreatic tumor growth and metastases in mice. But when combined with immunotherapy, the compound significantly shrank tumors and dramatically improved survival in the animals.
The findings, published July 3 in Science Translational Medicine, suggest that the immune-boosting compound could potentially make resistant pancreatic cancers susceptible to immunotherapy and improve treatment options for people with the devastating disease.
“Pancreatic cancer is a highly lethal disease, and we are in desperate need of new therapeutic approaches,” said co-senior author David DeNardo, PhD, an associate professor of medicine and of pathology and immunology at Washington University School of Medicine. “In animal studies, this small molecule led to very marked improvements and was even curative in some cases. We are hopeful that this approach could help pancreatic cancer patients.”
On paper, immunotherapies for pancreatic cancer seem like a good idea. The technique works by releasing a brake on specialized immune cells called T cells so they can attack the cancer. In the past, researchers working in the lab found they could release the brake and prod T cells into killing pancreatic cancer cells. But when doctors tried to treat people with pancreatic cancer using immunotherapies, fewer than five percent of patients improved.
This failure of immunotherapy in pancreatic cancer has puzzled scientists. But T cells aren’t the only player in the immune assault on cancer. Myeloid cells, another kind of immune cell found in and around tumors, can either tamp down or ramp up the immune response. They tilt the playing field by releasing immune molecules that affect how many T cells are recruited to the tumor, and whether the T cells show up at the tumors activated and ready to kill, or suppressed and inclined to ignore the tumor cells. In pancreatic tumors, myeloid cells typically suppress other immune cells, undermining the effects of immunotherapy.
DeNardo, co-senior author Vineet Gupta, PhD, of Rush University, and colleagues realized that releasing the brake on T cells might not be enough to treat pancreatic cancer. Unleashing the power of immunotherapy might require also shifting the balance of myeloid cells toward those that activate T cells to attack.
The researchers identified a compound, called ADH-503, that interferes with the migration of myeloid cells. Normally, pancreatic tumors are teeming with myeloid cells that suppress the immune response. When the researchers gave the compound to mice with pancreatic cancer, the number of myeloid cells in and near the tumors dropped, and the remaining myeloid cells were of the kind that promoted, rather than suppressed, immune responses. This environment translated into greater numbers of cancer-killing T cells in the tumor, significantly slower tumor growth and longer survival.
Then, the researchers – including first author Roheena Panni, MD, resident in general surgery at Washington University and Barnes-Jewish Hospital, and co-author William Hawkins, MD, the Neidorff Family and Robert C. Packman Professor of Surgery at Washington University School of Medicine – investigated whether creating this same environment could make pancreatic tumors susceptible to standard immunotherapy. First, they treated mice with a so-called PD-1 inhibitor, a standard immunotherapy used to treat other kinds of cancer. Unsurprisingly, they saw no effect. But when the researchers gave the mice the immunotherapy in conjunction with ADH-503, the tumors shrank and the mice survived significantly longer. In some experiments, all the tumors disappeared within a month of treatment, and all the mice survived for four months, when the researchers stopped monitoring them. In comparison, all the untreated mice died within six weeks.
Gupta noted that while pancreatic cancer is the third leading cause of cancer-related death in the United States, only about three percent of clinical trials for cancer immunotherapies target pancreatic cancer.
“Unlocking the promise of immunotherapies for pancreatic cancer requires a new approach,” Gupta said. “We believe these data demonstrate that targeting myeloid cells can help overcome resistance to immunotherapies.”
The strategy of boosting antitumor immune activity by shifting the balance of myeloid cells improved the effectiveness of other pancreatic cancer therapies as well, the researchers said. Mice treated with chemotherapy or radiation therapy both fared significantly better when ADH-503 was added to the regimen.
“You can’t make a one-to-one translation between animal studies and people, but this is very encouraging,” DeNardo said. “More study is needed to understand if the compound is safe and effective in people, which is why Gossamer Bio, Inc., is starting phase I safety studies in people later this year at Washington University and other sites.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Canceron October 7, 2020 at 5:04 am
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today ...
- NantKwest/ImmunityBio expand mid-stage pancreatic cancer studyon October 6, 2020 at 6:27 pm
NantKwest (NASDAQ:NK) and its collaborating partner ImmunityBio have announced to add a third cohort to ongoing Phase 2 immunotherapy trial for locally advanced or metastatic pancreatic cancer, and ...
- Yale cancer receives ACGT grant to advance strategies for treating pancreatic canceron October 6, 2020 at 6:40 am
Alliance for Cancer Gene Therapy (ACGT) gives $500,000 research grant to Sidi Chen, Ph.D., with Yale School of Medicine and Yale Cancer Center to advance strategies for treating pancreatic cancer ...
- Bob Gibson, the St. Louis Cardinals' dominating Hall of Fame pitcher, has died at 84 after fighting pancreatic canceron October 3, 2020 at 1:57 am
Bob Gibson, the St. Louis Cardinals' dominating Hall of Fame pitcher, has died at 84 after fighting pancreatic cancer ...
- Hall of Famer, Cardinals legend Bob Gibson dies at 84 after battle with pancreatic canceron October 2, 2020 at 8:32 pm
Gibson becomes the second Cardinals Hall of Famer to die in the last month along with Lou Brock who died September 6.
- LI's pancreatic cancer walk goes virtual during pandemicon October 1, 2020 at 1:31 pm
When the 20th Long Island Walk for Pancreatic Cancer Research steps off this weekend, a very special survivor will be leading the way virtually. Joel Evans, 72, a Commack resident who is a five-year p ...
- Nonprofit Raises $1 Million for Pancreatic Cancer Researchon September 30, 2020 at 5:38 am
Sept. 20, nonprofit Purple Pansies received more than $1 million in donations to help end pancreatic cancer in their ...
- Competitive Scenario of Pancreatic Cancer Treatment Drugs Market Growth, Size, Demand, Forecast with Depth Assessment by Top Key Players 2025on September 29, 2020 at 11:58 pm
Global ""Pancreatic Cancer Treatment Drugs Market""(2020-2026) status and position of worldwide and key regions, ...
- Hackensack Meridian CDI Scientists Find One-Two Punch Working Against Stubborn Pancreatic Cancer in Preclinical Modelson September 29, 2020 at 6:50 am
PRNewswire/ -- A one-two punch of changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of ...
- What coverage does Medicare provide for pancreatic cancer?on September 29, 2020 at 4:53 am
Medicare covers many treatments and services related to pancreatic cancer. Out-of-pocket costs may apply. Read on for more information.
via Bing News